These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29706950)

  • 21. Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
    Mendonça FM; Martín-Gutierrez FJ; Ríos-Martín JJ; Camacho-Martinez F
    Dermatology; 2016; 232(2):249-53. PubMed ID: 26820308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 23. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
    Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
    J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.
    Wu CY; Wu CY; Li CP; Chou YJ; Lin YH; Chang YT
    Diabetes Res Clin Pract; 2021 Jan; 171():108546. PubMed ID: 33232759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.
    de Nicolas-Ruanes B; Ballester-Martinez A; Garcia-Mouronte E; Berna-Rico E; Azcarraga-Llobet C; Fernandez-Guarino M
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
    Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
    Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
    Sugiyama S; Yamamoto T; Aoyama Y
    J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
    Kawaguchi Y; Shimauchi R; Nishibori N; Kawashima K; Oshitani S; Fujiya A; Shibata T; Ohashi N; Izumi K; Nishie W; Shimizu H; Arima H; Sobajima H
    J Diabetes Investig; 2019 Mar; 10(2):392-398. PubMed ID: 29920976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of IL-10 and IL-35 in dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Kokubu H; Takahashi T; Kabuto M; Kouzaki H; Fujimoto N
    Exp Dermatol; 2023 Sep; 32(9):1569-1574. PubMed ID: 37424368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gliptin-induced bullous pemphigoid.
    Ganeva M; Gancheva T; Manuelyan K; Hristakieva E
    Int J Clin Pharmacol Ther; 2024 Feb; 62(2):89-95. PubMed ID: 38032147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.
    Bukvić Mokos Z; Petković M; Balić A; Marinović B
    Croat Med J; 2020 Apr; 61(2):93-99. PubMed ID: 32378375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.
    Kinyó Á; Hanyecz A; Lengyel Z; Várszegi D; Oláh P; Gyömörei C; Kálmán E; Berki T; Gyulai R
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation.
    Kridin K; Avni O; Damiani G; Tzur Bitan D; Onn E; Weinstein O; Cohen AD
    Arch Dermatol Res; 2023 Jan; 315(1):33-39. PubMed ID: 35032198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
    Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
    Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
    J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Bellinato F; Maurelli M; Schena D; Gisondi P; Girolomoni G
    Ital J Dermatol Venerol; 2021 Aug; 156(4):455-459. PubMed ID: 32545941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
    Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
    Front Immunol; 2018; 9():1030. PubMed ID: 29881377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid.
    Nakahara Y; Yamane M; Sunada M; Aoyama Y
    J Dermatol; 2023 Feb; 50(2):162-165. PubMed ID: 36578130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.